Skip to main content
. 2013 Mar 26;8(3):e59693. doi: 10.1371/journal.pone.0059693

Figure 1. Experimental design in this study.

Figure 1

CsA was administered at a dose of 7.5 mg/kg subcutaneously daily. hATMSCs was infused at 0,1,2 and 3 weeks from the start of CsA with cell number of 3×106/mL via tail vein. hATMSCs; human adipose tissue derived mesenchymal stem cells.